Unveiling a new era in medical innovation, Noah Medical has proudly announced securing $150 million in Series B funding. This significant investment marks a pivotal moment for the company as it gears up to meet the surging demand for its groundbreaking Galaxy System, a cutting-edge solution in navigated robotic bronchoscopy.

Steering this funding round are Softbank Vision Fund and Prospertiy7 Ventures, underscoring the widespread confidence in Noah Medical's trajectory. Noteworthy participation also comes from esteemed entities including Hillhouse, Sequoia China, Shangbay Capital, Uphonest Capital, Summed Capital, Lyfe Capital, 1955 Capital, and AME cloud ventures, along with several undisclosed investors. This collective backing underscores the industry's recognition of Noah Medical's transformative potential.

Jian Zhang, the visionary founder and CEO of Noah Medical, expressed profound gratitude towards the investors, affirming their crucial role in propelling the company towards its mission. Zhang emphasized, "Next-generation robotics platforms like the Galaxy System are filling procedural gaps to provide superior clinical values to better serve customers’ needs." The alignment of vision between Noah Medical and its investors underscores a shared commitment to advancing medical care through technological innovation.

Central to the Galaxy System's prowess is its ability to enhance location accuracy and diagnostic efficacy in bronchoscopy procedures. With recent FDA clearance for commercial use in the United States, coupled with ongoing first-in-human trials at Macquarie University Hospital in Sydney, Australia, the system stands poised to revolutionize respiratory care on a global scale.

At the heart of the Galaxy System lies Noah Medical's proprietary TiLT+ Technology, a groundbreaking amalgamation of integrated tomosynthesis and augmented fluoroscopy. Complemented by a single-use disposable bronchoscope and a compact footprint, TiLT+ Technology represents a paradigm shift in overcoming CT to body divergency, thereby providing real-time navigation and lesion updates with unparalleled precision.

Distinctive to Galaxy's design is its purpose-built four-way bronchoscope articulation, facilitating navigation to peripheral lesions with unprecedented accuracy. As one of the few robotic-navigated bronchoscopy systems featuring a single-use disposable bronchoscope, Galaxy not only enhances efficiency and workflow but also mitigates cross-contamination risks, a paramount consideration in modern healthcare settings.

Despite Noah Medical's resounding success, the company finds itself embroiled in litigation from Auris, alleging misappropriation of trade secrets. In response, Noah Medical has initiated legal proceedings to dismiss the lawsuit, affirming its commitment to ethical business practices and safeguarding intellectual property rights.

In conclusion, Noah Medical's triumphant journey underscores the transformative impact of technological innovation in modern healthcare. With the Galaxy System poised to redefine bronchoscopy standards, Noah Medical stands at the vanguard of revolutionizing medical care, driven by a steadfast commitment to advancing patient outcomes and clinician experiences.